LMB033

LMB033 is a preclinical **light-activated oncolytic peptide** being developed by **Lumobiotics** for **bladder cancer**. It is described as a photocontrolled analog of gramicidin S that incorporates a diarylethene photoisomerizable fragment, enabling switching between an inactive closed form and an active open form upon irradiation. In its activated state, LMB033 targets the **cancer cell membrane** and induces direct cytolytic membrane damage; company materials indicate activation with **red light around 650 nm**, while research descriptions also note photoisomer control using other wavelengths. Available preclinical information suggests potent cytotoxicity in the activated state with lower activity in the inactive state, supporting spatially controlled antitumor activity, and some studies have suggested the potential to induce immunogenic cell death.

Other names

light-activated oncolytic peptidephotocontrolled analog of gramicidin S